Company Filing History:
Years Active: 2010-2012
Title: Innovations of Géza Ambrus-Aikelin
Introduction
Géza Ambrus-Aikelin is a notable inventor based in Keszthely, Hungary. He has made significant contributions to the field of biochemistry, particularly in the area of serine proteases. With a total of two patents to his name, his work has implications for both research and clinical applications.
Latest Patents
His latest patents focus on "Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof." This invention pertains to unglycosylated folded C-terminal fragments of a multidomain serine protease of the complement cascade, which can be obtained through expression in a bacterial host. The serine protease is capable of binding to recognition molecules of the complement cascade, such as C1 or MBL. The patents also detail methods and bacterial expression vectors for preparing these fragments, as well as their uses in raising antibodies and screening substrates or inhibitors of serine proteases. Furthermore, the invention provides assay methods for assessing MASP-1 and MASP-2 levels in biological samples, offering valuable research tools, assays, and diagnostic kits for complement research and related disorders.
Career Highlights
Géza Ambrus-Aikelin is associated with Targetex Kft., where he continues to innovate and contribute to advancements in his field. His work is characterized by a strong focus on the practical applications of his inventions, particularly in the context of medical research and diagnostics.
Collaborations
He has collaborated with notable colleagues such as Péter Gál and Péter Závodszky, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Géza Ambrus-Aikelin's contributions to the field of biochemistry through his patents on serine proteases highlight his innovative spirit and dedication to advancing scientific knowledge. His work not only furthers research but also holds promise for clinical applications in the treatment of complement-related disorders.